2024, Number 6
Med Int Mex 2024; 40 (6)
Early initiation of immunoglobulin in acute inflammatory demyelinating polyradiculoneuropathy associated with SARS-CoV-2
Rosado CRA, Solís PRJ, Rodríguez MSM
Full text
Language: Spanish
References: 4
Page: 395-397
PDF size: 197.88 Kb.
ABSTRACT
Background: Due to the COVID-19 pandemic that began in 2019, various neurological manifestations associated with SARS-CoV-2 infection have been reported, among which Guillain-Barre syndrome stands out. Delayed diagnosis as well as late initiation of treatment can cause poor short-term prognosis and loss of function in patients.Clinical case: A 57-year-old male patient with no history of chronic degenerative diseases, functional for basic and instrumental activities of daily living, vaccinated with an AstraZeneca dose against COVID-19 that initiated symptoms with liquid evacuations, positive SARS-CoV-2 PCR was reported; a few days after his diagnosis patient showed progressive ascending weakness. When Guillain-Barre syndrome was suspected treatment with immunoglobulin was given, obtaining favorable response.
Conclusions: In Mexico 63-75% of patients with COVID-19 start treatment with immunoglobulin, so it is important to consider Guillain-Barre syndrome a differential diagnosis before the acute onset of weakness after a history of infection by SARS-CoV-2, since a delay can lead to late start of treatment with short-term impact on the functionality of patients.
REFERENCES